Clinical Trial: Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793956) titled 'Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma' on Jan. 21.

Brief Summary: This is an open-label, phase Ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (NKTCL).

Study Start Date: Jan. 31

Study Type: INTERVENTIONAL

Condition: Extranodal Natural Killer/T Cell Lymphoma

Intervention: DRUG: Sintilimab and Linperlisib Combination Treatment

Sintilimab administered via intravenous infusion; Linperlisib administered orally.

Recruitment Status: NOT_YET_RECRU...